

MedStar Health, Inc.

POLICY AND PROCEDURE MANUAL

Policy Number: MP.126.MH
Last Review Date: 08/10/2017
Effective Date: 10/01/2017

MP.126.MH – Cell-Free DNA Test

This policy applies to the following lines of business:

- ✓ MedStar Employee (Select)
- ✓ MedStar MA – DSNP – CSNP
- ✓ MedStar CareFirst PPO

Cell-free fetal DNA testing has been validated for testing for Trisomy 21 (T21 or Down Syndrome). It may also detect Trisomy 18 (T18 or Edwards Syndrome) or Trisomy 13 (T13 or Patau Syndrome), but at this time, screening for those conditions is not considered medically necessary or appropriate.

According to the American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine, the test may be used for the following high-risk women:

- Women aged 35 years or older
- Fetuses with ultrasonographic findings that indicate an increased risk of aneuploidy
- Women with a history of a child affected with a trisomy
- Positive test result for aneuploidy, including first trimester, sequential, or integrated screen, or a quadruple screen
- Parent carrying a balanced robertsonian translocation with increased risk of trisomy 13 or trisomy 21

Limitations

1. Cell-free fetal DNA testing should not be part of routine prenatal laboratory assessment, but should be an informed patient choice after pretest counseling.
2. Cell-free fetal DNA testing should not be offered to low-risk women or women with multiple gestations because it has not been sufficiently evaluated in these groups.

Background

ACOG estimates that 6-11% of stillbirths and neonatal deaths result from aneuploidies (fetus with missing or extra chromosomes). Most aneuploidies involve the presence of an extra chromosome, also referred to as trisomy.

Down syndrome, which is most commonly caused by trisomy 21 (T21), is routinely evaluated as the standard of care for the majority of the 4 million women who give birth each year in the United States. Conventional screening tests typically involve measurement of blood serum markers in conjunction with ultrasound followed by recommendation for diagnostic invasive procedures for abnormal results from screening.

MP.126.MH – Cell-Free DNA Test

Policy Number: MP.126.MH
Last Review Date: 08/10/2017
Effective Date: 10/01/2017

First trimester combined screening (FTS) and integrated screening (INT) have the best screening performance, yet still only have T21 detection rates of 82-87% and 88-95%, respectively, at false positive rates of 5%. Invasive testing with amniocentesis or CVS is highly accurate but has up to a 3% risk of procedure related miscarriage. The reported complication rates have come down in the last 10 years, but there is still some procedure-related risk. A prenatal test that evaluates cell-free DNA (cfDNA) in maternal blood has recently become available. Testing for cfDNA has been shown to be highly accurate, with T21 detection rates >99% at false positive rates <0.1%, across numerous studies in the high-risk population of pregnant women.

cfDNA testing, when used for high-risk women can detect more T21 cases and at the same time reduce unnecessary invasive procedures and in turn fewer procedure related fetal losses. cfDNA testing, when used as a follow-up test for an abnormal result from the FTS or INT screening test for low risk women can spare the vast majority of the 5% of women with false positive results from undergoing invasive confirmatory testing. Any woman with an abnormal result from cfDNA test should undergo confirmatory testing by amniocentesis or chorionic villus sampling.

Currently, there are five noninvasive prenatal testing (NIPT) assays available in the United States: Harmony Prenatal Test, informaSeq, MaterniT21 PLUS, Panorama Prenatal Test, and Verifi Prenatal Test (the assays are listed in order of market entrance date). The assays involve the analysis of cfDNA present in a mother's blood during pregnancy to detect aneuploidies involving specific chromosomes (typically test for chromosomes 21, 18, 13 and the sex chromosomes).

Further validation is being performed to determine whether the tests are as useful in multiple gestations (twins, triplets, etc.), as well as the predictive value for translocations, trisomy 13 and 18, and aneuploidy of sex chromosomes.

The prevalence of aneuploidies is infrequent enough in the low-risk population to make the false positive and false negative rate problematic if the test were to be performed on all pregnant women. In addition, since there is a low false positive rate, a confirmatory invasive procedure (amniocentesis or cvs) should be performed on all abnormal results.

Codes:

CPT Codes / HCPCS Codes / ICD-10 Codes

Code	Description
------	-------------

CPT Codes

MP.126.MH – Cell-Free DNA Test

Policy Number: MP.126.MH

Last Review Date: 08/10/2017

Effective Date: 10/01/2017

81507	Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy
81599	Unlisted multianalyte assay with algorithmic analysis
ICD-10 codes covered if selection criteria are met:	
O35.1XX0- O35.1XX9	Maternal care for (suspected) chromosomal abnormality in fetus
O35.8XX0- O35.8XX9	Maternal care for other (suspected) fetal abnormality and damage
O35.9XX0- O35.9XX9	Maternal care for (suspected) fetal abnormality and damage, unspecified
O09.511- O09.519	Supervision of elderly primigravida
O09.521- O09.529	Supervision of elderly multigravida
O28.0-O28.9	Abnormal findings on antenatal screening of mother

References

1. Caughey AB, Hopkins LM, Norton ME, Chorionic villus sampling compared with amniocentesis and the difference in the rate of pregnancy loss. *Obstet Gynecol.* 2006 Sep;108(3 Pt 1):612-616. <http://www.ncbi.nlm.nih.gov/pubmed/16946222>
2. Chiu RW, Chan KC, Gao Y, et al. Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. *Proc Natl Acad Sci U S A.* 2008 December 23; 105(51): 20458–20463. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2600580/pdf/zpq20458.pdf>
3. Hayes GTE Overview. Harmony Prenatal Test. March 5. 2015.
4. Hayes GTE Overview. Panorama Prenatal Test. March 5. 2015.
5. Hayes GTE Overview. Verifi Prenatal Test. March 5. 2015.
6. Hayes GTE Report. Noninvasive Prenatal Testing (NIPT). March 5, 2015.
7. Hahn S, Lapaire O, Tercanli S, et al. Determination of fetal chromosome aberrations from fetal DNA in maternal blood: has the challenge finally been met? *Expert Rev Mol Med.* 2011 May 4; 13:e16. doi: 10.1017/S1462399411001852., <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3087311/pdf/S1462399411001852a.pdf>
8. Kollmann M, Haeusler M, Haas J, et al. Procedure-Related Complications after Genetic Amniocentesis and Chorionic Villus Sampling, *Ultraschall Med.* 2012 Jun

MP.126.MH – Cell-Free DNA Test

Policy Number: MP.126.MH
Last Review Date: 08/10/2017
Effective Date: 10/01/2017

21. DOI: 10.1055/s-0032-1312939.
<http://www.ncbi.nlm.nih.gov/pubmed/22723040>
9. National Institutes of Health, National Library of Medicine. Genetics Home Reference, Trisomy 13, Reviewed November 2013.
<http://ghr.nlm.nih.gov/condition/trisomy-13>
10. National Institutes of Health, National Library of Medicine. Genetics Home Reference: Trisomy 18, Reviewed March 2012,
<http://ghr.nlm.nih.gov/condition/trisomy-18>
11. National Institutes of Health, National Library of Medicine. Genetics Home Reference: Down Syndrome, Reviewed June 2012,
<http://ghr.nlm.nih.gov/condition/down-syndrome>
12. National Institutes of Health, National Library of Medicine. Medline Plus: Quadruple screen test. Updated 2/26/2012,
<http://www.nlm.nih.gov/medlineplus/ency/article/007311.htm>
13. National Institutes of Health, National Library of Medicine. PubMed Health. A.D.A.M. Medical Encyclopedia, Amniocentesis. Reviewed August 5. 2013,
<http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0004369/>
14. National Institutes of Health, National Library of Medicine. PubMed Health. A.D.A.M. Medical Encyclopedia: Chorionic Villus Sampling. Reviewed August 7, 2012, <http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0003884/>
15. Noninvasive prenatal testing for fetal aneuploidy. Committee Opinion No. 545, December 2012. American College of Obstetricians and Gynecologists [ACOG]. Obstet Gynecol. 2012; 120:1532–1534.
http://www.acog.org/Resources_And_Publications/Committee_Opinions/Committee_on_Genetics/Noninvasive_Prenatal_Testing_for_Fetal_Aneuploidy
16. Rare Chromosome Disorder Support Group. Robertsonian Translocations, information verified by Dr Caroline Ogilvie, principal scientist, Cytogenetics Department, Guy's and St Thomas' Hospital Trust and by Professor Maj Hulten, Professor of Medical Genetics, Warwick University, UK 2005. © Unuque, 2005. Available at:
<http://www.rarechromo.org/information/Other/Robertsonian%20Translocations%20FTNW.pdf>
17. Scott F, Peters H, Boogert T, et al. The loss rates for invasive prenatal testing in a specialised obstetric ultrasound practice. Aust N Z J Obstet Gynaecol. 2002 Feb;42(1):55-58, <http://www.ncbi.nlm.nih.gov/pubmed/11926642>
18. Song K, Musci T, Caughey AB. Clinical Utility and Cost of Non-Invasive Prenatal Testing with cfDNA Analysis in High Risk Women Based on a US Population. Journal of Maternal-Fetal and Neonatal Medicine. doi: 10.3109/14767058.2013.770464 http://www.cammonza.com/sites/default/files/public/contributi/13022013_Song_Musci_Caughey_JMaternFetalNeonatalMed.pdf

MP.126.MH – Cell-Free DNA Test

Policy Number: MP.126.MH

Last Review Date: 08/10/2017

Effective Date: 10/01/2017

19. Wright CF, Burton H., The use of cell-free fetal nucleic acids in maternal blood for non-invasive prenatal diagnosis. Hum Reprod Update. 2009 Jan-Feb; 15(1):139-51. doi: 10.1093/humupd/dmn047. Epub 2008 Oct 22.

<http://humupd.oxfordjournals.org/content/15/1/139.full.pdf+html>

Disclaimer:

MedStar Health medical payment and prior authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. The policies constitute only the reimbursement and coverage guidelines of MedStar Health and its affiliated managed care entities. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies.

MedStar Health reserves the right to review and update the medical payment and prior authorization guidelines in its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.

These policies are the proprietary information of Evolent Health. Any sale, copying, or dissemination of said policies is prohibited.